breaking biotech news hey thought might want take look gtha could genethera become next darling biotech announce collaborations industry giant beckman coulter breaking biotech news genethera inc collaborate biotech giant beckman coulter inc genethera news release july 11 th 2005 genethera inc otc bb gtha molecular biotech company located wheat ridge co granted first right refusal beckman coulter inc nyc bec 63 34 license genethera patented technology developing live animal genetic diagnostic tests significant milestone genethera beckman coulter one world leading manufacturers biomedical testing systems tests supplies collaboration unite expertise beckman coulter cutting edge technology genethera dr antonio milici ph genethera inc genethera provides genetic diagnostic solutions veterinary agricultural industries future plans include healthcare industry company formed realize commercial potential molecular diagnostic assays using roche f pcr technology detect presence infectious disease blood animals particularly live animals platform enables genethera offer tests presently available technology future plans include infectious disease potentially affecting domesticated livestock well wildlife intended human consumption priority given mad cow johne foot mouth diseases cattle genethera successfully developed ability detect mad cow disease chronic wasting disease cwd also known mad deer elk free information reguarding stocks e mail first name last name phone number view full report view full report company genethera inc symbol gtha exchange otc bb recent price 0 90 outstanding shares 21 mil website www genethera net prior 1 st case mad cow u beef exports 2003 us valued near 6 billion export dollars since lost international us beef ban imposed 2004 90 million cattle feedlots u 35 million cattle slaughtered u annually beckman coulter inc leading manufacturer biomedical testing instrument systems tests supplies simplify automate laboratory processes spanning biomedical testing continuum pioneering medical research clinical trials laboratory diagnostics point care testing beckman coulter 200 000 installed systems provide essential biomedical information enhance health care around world company based fullerton calif reported 2004 annual sales 2 4 billion 64 percent amount generated recurring revenue supplies test kits services information visit www beckmancoulter com looking forward working genethera identify commercial applications technology chris neary general manager prion business center beckman coulter inc countries around globe discovery cow mad cow disease leads immediate slaughter hundreds even thousands cattle wide spread fear disease spread need complete disease testing dead animals costly international beef recalls common since mad cow testing conducted slaughter process genethera live animal blood test could lead halting mass slaughters widespread panic saving industry hundreds millions dollars year testing single blood sample genethera could end need slaughter entire herds cattle animals disease testing saving industry hundreds millions dollars year currently funded institutional money manager southern california genethera plans open laboratories worldwide meet exploding bse testing demand want invest dna revolution wait customized drugs years away buy shares company using dna diagnostic work forbes good genes kerry dolan may 16 2005 new patented tests created information gleaned genome mapping injected new life higher margins near 75 business 2 5 billion molecular diagnostics industry expanding 15 annual rate according consulting firm leomics associates emerson n j genethera gtha making mark biotech genethera recently teamed biotech giant beckman coulter inc first market blood test mad cow disease live cattle ability detect numerous infectious diseases utilizing genetic methods blood live animal first market blood test detecting cwd presently developing therapeutic vaccine cwd mad cow disease using rna interference technology currently developing blood test using platform breast prostate cancer detection strategic partner xpng xpention genetics inc genethera could end beef recalls potentially slaughter millions animals around globe saving industry hundreds millions dollars year currently funded institutional money manager southern california genethera plans open laboratories worldwide handle growing bse testing demand genethera could generate revenues 13 million every 1 cattle tested usa alone international testing figures would staggering genethera technology genethera business based integrated technology platform itp combines proprietary diagnostic solution called gene expression assay gea tm purivax tm system analyzing large scale dna sequencing first part platform ongoing development molecular diagnostic assays solutions using real time fluorogenic polymerase chain reaction f pcr technology detect presence infectious disease blood live animals second part itp development therapeutic vaccines using rna interference technology also allows efficient effective continuous testing management treatment animal populations facts distinguish technology alternative testing management methodology available agriculture today require destruction individual animals even entire herds testing data analysis processes also allow us separate infected clean animals also gain knowledge vital development preventative vaccines genethera inc committed providing global access cutting edge biotechnology services fellow scientists academia pharmaceutical industry biotechnology industry primarily genethera expertise focuses technology relevant animal human immunotherapy genethera dedicated furnishing dependable high quality cost effective prompt client consulting services services backed cumulative experiences greater 100 years research development government industry genethera senior scientists genethera develops commercial scale implementation adenovector purification process support rd material production furthermore genethera evaluates tests commercially available expression vectors incorporates vector repertoire technologies well established within repertoire genethera scientific staff genethera uniquely detect treat variety diseases animals still alive company provides genetics based diagnostic vaccine solutions meet growing demands today veterinary industry tomorrow agriculture healthcare industries company organized operated continually apply scientific research effective management diseases realize commercial potential molecular biotechnology core genethera operation ongoing development molecular diagnostic assays using real time fluorogenic polymerase chain reaction f pcr technology uses live animal blood detect presence infectious diseases development vaccines blood born diseases also allows efficient effective continuous testing management treatment animal populations facts distinguish technology alternative testing management methodology available agriculture today require destruction individual animals even entire herds testing data analysis processes also allow us separate infected clean animals also gain knowledge vital development preventative vaccines date genethera successfully developed assay ability detect mad cow chronic wasting disease disease affecting elk deer north america diagnostic assays e coli ol 57 h 7 johnne disease final stages development vaccines e coli ol 57 h 7 johnne disease diseases affecting cattle advanced stages development future company plans expand assay application research wide range diseases animals immediate targets mad cow hoof mouth west nile newcastle genethera detect bse using companies patented live animal blood test evaluates e r f gene sequence e r f gene proven decrease dramatically tse infection noticeable live animal human patent gtha holds broad based detect tse diseases including mad cow bse cattle cwd elk deer creutzfeld jacobs humans company patented test detect diseases faster method developed marketplace far less cost test also used mass scale using roche f pcr dna analyzing robotics equipment genethera analyze 2000 blood samples day one f pcr machine single technician project prove highly profitable approx 4 00 per test wide scale commercialization way multi billion dollar international demand commercial mad cow testing emerged around globe japan conducted 3 million post mortem rapid mad cow tests last year alone used western blot developed prionics ag swizterland bio rad rapid test costs 20 40 dollars per test importantly tests marketplace detect disease animal killed testing post mortem brain tissue exams extremely labor intensive costly japan spent 60 million 120 million 3 million post mortem rapid mad cow tests 2004 genethera simple blood test collected using patented field collection system sample mailed lab testing company also stated recent 10 k currently negotiations strategic testing partners believe absorb costs commercializing live animal mad cow test management dr tony milici chairman board president ceo dr milici ph experimental hematology medicine surgery receiving degrees university rome italy stanford university specialties include molecular biology biotechnology gene therapy molecularly oncology molecular extensive post graduate training includes fellowship department clinical immunology university texas anderson cancer center visiting fellow university rome laboratory cellular immunology biochemistry among post graduate activities dr milici assistant professor medical college georgia department pharmacology toxology well assistant biochemist department molecular pathology university texas anderson cancer center houston tx prior founding genethera inc dr milici president ceo genetrans inc based augusta ga diagnostics laboratory dr milici genethera realization ambition demonstrate commercial potential molecular biotechnology dr thomas j slaga board member dr slaga ph physiology biophysics undergraduate degrees biology chemistry since 1999 dr slaga served adjunct professor department biochemistry molecular biology university colorado health sciences center located denver co dr slaga career steeped research development roles affiliations concentrating cancer examples include chair scientific director cancer causation prevention amc cancer research center located denver co director professor biochemistry university texas anderson cancer center science park research division located smithville tx group leader research staff member skin carcinogenesis tumor promotion biology division oak ridge national laboratory oak ridge tn dr slaga blend scientific management experience lends genethera board important dimension vis vis development opportunities mr richard w bryans jr board member general counsel mr bryans attorney law denver co graduate regis university business administration economics mr bryans went graduate university denver college law practicing law denver 12 years mr bryans provides genethera board much valued legal perspective benefit young publicly traded company additionally company able take advantage mr bryans legal experience important area vaccine licensing integral future genethera join market movers mailings click find tw inc 4636 hidden forest dr sarasota fl 32430 disclaimer publicly distributed email report otc special situations report publication otc growth stock watch sponsored advertisement paid advertising issue otc growth stock watch purport provide analysis company financial position way construed offer solicitation buy sell security otc growth stock watch paid advertiser xpention genetics inc featured company distribution costs report new subscribers eighty thousand dollars funded tw inc effort create investor awareness xpention genetics inc tw inc broker dealer investment advisor market movers otc growth stock watch otc special situations report geoffrey eiten considered broker dealer though investment advisors anticipated report generate new subscriptions growth stock watch neither otc growth stock watch geoffrey eiten reviewer analyst received compensation report expect receive unknown amount revenue new subscriptions subscription offer contained herein report including opinions expressed statements made within informational advertising purposes construed investment advice constitute offer sell securities soliciting offer buy securities state jurisdiction offer sale permitted readers consult professional investment tax portfolio advisors making investment decision independently verify information herein information used prepare report believed reliable sources representation made accuracy completeness information investment securities carries high degree risk involves risks uncertainties may result investors losing invested capital past performance guarantee future results information contained herein contains forward looking statements within meaning section 27 securities act 1933 section 21 e securities exchange act 1934 forward looking statements based upon expectations estimates projections time statements made involve risks uncertainties could cause actual events differ materially anticipated forward looking statements may identified use words expects anticipates estimates believes statements indicating certain actions may could might occur statements express involve predictions expectations beliefs plans projections objectives goals future events performance may forward looking statements factors could cause actual results differ materially include limited adverse economic conditions intense competition lack meaningful research results inadequate capital termination contracts agreements adverse publicity news coverage inability carry research development commercialization plans loss retirement key executives research scientists risks detailed company reports filed securities exchange commission complete information xpention genetics inc available website securities exchange commission http www sec gov copies filings may read without charge copies obtained prescribed rates public reference facilities commission 450 fifth street nw washington dc 20549 media matrix 7025 county rd 46 dte 1071 349 lake mary fl 32746 e mail message advertisement solicitation